Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 10/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | ACR | P10323 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988719 | 0.89 | MAPT (0.45) | STSLMNANPC1MAPTRAB9A | |
| SCHEMBL15398648 | 0.81 | STS (0.64) | STSLMNANPC1MAPTRAB9A | |
| SCHEMBL27134697 | 0.78 | STS (0.64) | STSLMNAMAPTALDH1A1ELANE | |
| SCHEMBL12966544 | 0.78 | KMT2A (0.46) | STSNPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL17988683 | 0.77 | STS (0.66) | STSLMNANPC1MAPTRAB9A | |
| SCHEMBL27029727 | 0.77 | STS (0.62) | STSLMNAMAPTALDH1A1ELANE | |
| SCHEMBL12966550 | 0.76 | LMNA (0.46) | LMNANPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL17992016 | 0.75 | LMNA (0.55) | LMNANPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL12966653 | 0.74 | MAPT (0.55) | LMNANPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL17988680 | 0.74 | MAPT (0.42) | STSLMNANPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686298-B1 | SUBSTITUTED DIPHENYL DERIVATIVES | CREATIVE THERAPEUTICS GMBH (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-9409859-B2 | Substituted diphenyl derivatives | CREATIVE THERAPEUTICS GMBH (DE) | 2016-08-09 | — | — | US | disclosed |
| EP-2686298-A1 | SUBSTITUTED DIPHENYL DERIVATIVES | Creative Therapeutics GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005149-A1 | Substituted diphenyl derivatives | CREATIVE THERAPEUTICS GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| WO-2012122969-A1 | SUBSTITUTED DIPHENYL DERIVATIVES | CREATIVE THERAPEUTICS GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005149-A1 | Substituted diphenyl derivatives | DPYD, VHL, TP53 | STS 3633/4885LMNA 4060/4885NPC1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.